IMAGE SOURCE: GETTY IMAGES.
Snag a much-needed Food and Drug Administration approval? Check. Increase the company’s market cap by over 120% in a matter of days? Check. Sarepta Therapeutics (NASDAQ: SRPT) managed to do both, thanks to a stunning regulatory win for Duchenne muscular dystrophy (DMD) drug Exondys 51. Removed risk for investors? Check back later.